Kimberly-Clark offers EU concessions for Kenvue deal
Kimberly-Clark has proposed remedies to address antitrust concerns regarding its acquisition of Kenvue. The European Commission extended its review deadline to October 13 while gathering feedback.
Xurve View
Insights:
Xurve View
KIMBERLY-CLARK CORP has offered antitrust remedies to the European Commission for its $40B acquisition of Tylenol maker KENVUE INC during late Wednesday afternoon negotiations. The EU regulator extended its review deadline to October 13 from September 29 to evaluate the proposed concessions. The transaction faces regional scrutiny as competition authorities weigh market concentration across consumer health brands.
